Outcomes With FOLFIRINOX for Borderline Resectable and Locally Unresectable Pancreatic Cancer

Journal of Surgical Oncology - United States
doi 10.1002/jso.23392
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Folfirinox Neoadjuvant Therapy for Locally Advanced and Borderline Resectable Pancreatic Cancer - A Retrospective Study

International Journal of Contemporary Medical Research [IJCMR]
2019English

Neoadjuvant FOLFIRINOX for Patients With Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis

Oncologist
Cancer ResearchMedicineOncology
2019English

NeoadjuvantNab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX

Anticancer Research
MedicineCancer ResearchOncology
2018English

Systematic Review of FOLFIRINOX in Patients With Locally Unresectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2016English

Operative Outcomes Following Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy (Sbrt) for Borderline Resectable and Locally Advanced Pancreatic Cancer

HPB
HepatologyGastroenterology
2019English

Complete Pathological Response Following Neoadjuvant FOLFIRINOX in Borderline Resectable Pancreatic Cancer - A Case Report and Review

BMC Cancer
Cancer ResearchOncologyGenetics
2016English

Management of Borderline Resectable Pancreatic Cancer

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2018English

Cutting‐edge Strategies for Borderline Resectable Pancreatic Cancer

Annals of Gastroenterological Surgery
2019English

Preoperative Nomogram to Predict Survival for Patients With Resectable and Borderline Resectable Pancreatic Cancer

HPB
HepatologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy